Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab

Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab

IntroductionIn immunocompromised patients, Epstein-Barr virus (EBV) infection or reactivation is associated with increased morbidity and mortality, including the development of B-cell lymphomas. The first-line treatment consists of reduction of immunosuppression and administration of rituximab (anti...

Full description

Bibliographic Details
Main Authors: Sabine Tischer-Zimmermann, Agnes Bonifacius, Maria Michela Santamorena, Philip Mausberg, Sven Stoll, Marius Döring, Ulrich Kalinke, Rainer Blasczyk, Britta Maecker-Kolhoff, Britta Eiz-Vesper
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
rituximab
cross-presentation
Epstein-Barr virus (EBV)
cytotoxic T cells (CTL)
EBV+ B-LCLs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.878953/full

Similar Items

Similar Items